We are relentlessly pursuing excellence – daring to believe that a cure can be a reality.
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies, Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies, Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2001
Investors 5
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Aisling Ca... | aislingcap... |
| - | Prospect V... | prospectve... |
| - | Advent Lif... | adventls.c... |
| - | Koa Labs | koalab.com |
Mentions in press and media 3
| Date | Title | Description |
| 09.01.2020 | Infinity Pharmaceuticals Raises $20 Million | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P., Infinity’s largest shareholder. This investment by BVF entails no equ... |
| 05.05.2009 | Group Names IBM, Zeemote, Infinity, Wolfe Executives as Leading Women Entrepreneurs | Share Share on Facebook Share on Twitter LinkedIn Email Reprints A study last year by Cristian Dezsö, an assistant professor at the University of Maryland’s business school, found that the more women a company has as senior managers, the be... |
| - | Discovered in the valley of the one-eyed lambs, a toxic weed fuels a cancer-drug gold rush — and a quandary | Eros Dervishi for STAT PHILADELPHIA — The search began immediately after breakfast. It was Sunday, the last morning of a conference for patients with Gorlin syndrome, and as Kaylene Sheran finished up her bacon and eggs, Sara Ann Conkling t... |